Discovery and identification of anti-U1-A snRNP antibody in lung cancer.
There are multiple reports of autoimmune response in patients with lung cancer. To investigate whether a novel autoantibody is present in patients with lung cancer and evaluate its clinical diagnostic and prognostic value, sera from 10 patients with lung cancer and 10 normal individuals were analyzed using immunofluorescence and Western blotting. It was found that one serum sample from the patients with squamous carcinoma gave a fine speckled pattern staining in nucleus and had a high titer antinuclear autoantibody which could recognize 31 kD of nuclear protein isolated from both cancer cells and normal cells. The same patient's serum was further used to immunoprecipitate the target antigen. The protein bands were excised from the SDS-PAGE gels and were analyzed with a Qstar Pulser I Quadrupole time-flight mass spectrometer, and the 31 kD target antigen was identified as U1-A snRNP. To test the prevalence of anti-U1-A snRNP antibody, sera from 93 patients including 36 squmaous carcinomas (SCC), 26 adenocarcinomas (Ad), and 31 small cell carcinomas (SCLC) were screened by Western blotting. The results demonstrated that anti-U1-A snRNP antibody was present in 50% of SCC sera, 26.9% of Ad sera and 54.8% of SCLC sera. In this paper, we report for the first time that anti-U1-A snRNP antibody could be detected in the patients with lung cancer.
Zhang
Lijuan
L
Key Laboratory of Cell Proliferation and Regulation of Ministry of Education, Beijing Normal University, Beijing 100875, China.
Liu
Jifu
J
Zhang
Hao
H
Wu
Shanshan
S
Huang
Lingyun
L
He
Dacheng
D
Xiao
Xueyuan
X
D000230:Adenocarcinoma / Q000175:diagnosis / Q000276:immunology; D000912:Antibodies, Neoplasm / Q000097:blood / Q000302:isolation & purification*; D001323:Autoantibodies / Q000097:blood / Q000302:isolation & purification*; D015153:Blotting, Western / Q000379:methods; D018288:Carcinoma, Small Cell / Q000175:diagnosis / Q000276:immunology; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000276:immunology; D016022:Case-Control Studies; D019084:Fluorescent Antibody Technique, Indirect / Q000379:methods; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000276:immunology*; D008297:Male; D009687:Nuclear Proteins / Q000276:immunology; D015995:Prevalence; D011379:Prognosis; D040081:Protein Array Analysis / Q000379:methods; D016601:RNA-Binding Proteins / Q000276:immunology*; D017412:Ribonucleoprotein, U1 Small Nuclear / Q000276:immunology*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods
D000912:Antibodies, Neoplasm; D001323:Autoantibodies; D009687:Nuclear Proteins; D016601:RNA-Binding Proteins; D017412:Ribonucleoprotein, U1 Small Nuclear; C075339:U1A protein